Acute Tubulointerstitial Nephritis Induced by Deferasirox following Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia
Korean Journal of Hematology
;
: 258-262, 2008.
Artículo
en Coreano
| WPRIM
| ID: wpr-720441
ABSTRACT
Deferasirox is a once-daily, oral iron-chelating agent that is now widely available for the treatment of transfusional hemosiderosis. Deferasirox represents a significant advance in the treatment of iron overload, as the availability of an effective oral therapy has the potential to relieve many patients from the burden of frequent parenteral therapy with the previous reference standard iron chelator, deferoxamine. The well-known drug-related adverse events associated with deferasirox include gastrointestinal disturbances, rash, elevations in liver enzyme levels, and mild increases in serum creatinine levels, but acute renal failure is not common. The authors report a case of acute tubulointerstitial nephritis induced by deferasirox following hematopoietic stem cell transplantation for severe aplastic anemia
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Triazoles
/
Benzoatos
/
Células Madre Hematopoyéticas
/
Trasplante de Células Madre Hematopoyéticas
/
Sobrecarga de Hierro
/
Creatinina
/
Deferoxamina
/
Exantema
/
Lesión Renal Aguda
/
Hemosiderosis
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Hematology
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS